ArticleInternational journal of molecular sciences2025
Topical Molecular Iodine: An Optimal Biocide Constrained by Inadequate Formulations.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The only biocidal iodine species in topical iodine disinfectants is molecular iodine (I2). I2, a biomolecule, has broad-spectrum antimicrobial activity and does not generate resistance. Physicians, regulatory agencies, and scientists have assumed that I2 is responsible for the skin staining and irritation associated with the clinical use of iodine disinfectants; this assumption is deeply embedded in the medical community but is not supported with empirical data. This study provides the first experimental data that measure the biocompatibility of I2 with human skin. Human skin explants in tissue culture were evaluated at 3, 7, and 24 h after being exposed to I2 (500 to 15,000 ppm). Cell viability was measured relative to phosphate-buffered saline using 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl-tetrazolium bromide (MTT). The biocidal activity of I2 vapor emitted from silicone was demonstrated against bacteria growing on agar to confirm I2 off-gassing from skin was an active biocide. Additionally, statistically significant bacterial reductions with both gas and solution phase I2 were observed in a static and dynamic five-species wound biofilm. The data suggest that high, e.g., 50-5000 ppm, levels of I2 should be incorporated into topical iodine disinfectants instead of the very low (0.2-10 ppm) levels found in 10% povidone iodine products currently in use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.